This report provides comprehensive information on the therapeutic development for — Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.
Get discount on this research report at http://www.reportsnreports.com/contacts/Discount.aspx?name=468277 .
Companies discussed in this research report are Abeome Corporation, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, Akron Molecules AG, Alize Pharma SAS, Amabiotics SAS, Ambrx, Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Asubio Pharma Co., Ltd., AtheroNova Inc., Avaxia Biologics, Inc., BioLingus AG, BioRestorative Therapies, Inc., BioTime, Inc., Boehringer Ingelheim GmbH, Braasch Biotech LLC, Bristol-Myers Squibb Company, Camurus AB, Carmot Therapeutics, Inc., Chronos Therapeutics Limited, CohBar, Inc., CoMentis, Inc., Daiichi Sankyo Company, Limited, Deltanoid Pharmaceuticals Inc., Diabetica Limited, DiscoveryBiomed, Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperion Therapeutics, Inc., Euroscreen S.A., F. Hoffmann-La Roche Ltd., FibroGen, Inc., Galenea Corp., Genfit SA, GlaxoSmithKline Plc, GTx, Inc., Gubra ApS, Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Helsinn Healthcare S.A., Hyundai Pharmaceutical Co., Ltd., Insusense Therapeutics ApS, Ionis Pharmaceuticals, Inc., Jenrin Discovery, Inc., Johnson & Johnson, Kainos Medicine, Inc., Kissei Pharmaceutical Co., Ltd., Lead Discovery Center GmbH, LEO Pharma A/S, LG Life Science LTD., M Pharmaceutical Inc., Magnus Life Science, MAKScientific, LLC, MedImmune, LLC, Mitsubishi Tanabe Pharma Corporation, Molecular Design International, Inc., NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, nLife Therapeutics, S.L., Nordic Bioscience A/S, Novo Nordisk A/S, ObeTherapy Biotechnology, Omeros Corporation, OPKO Health, Inc., Orbis Biosciences, Inc., Orchid Chemicals & Pharmaceuticals Ltd, Orexigen Therapeutics, Inc., Pfizer Inc., PharmaIN Corporation, PolyNovo Limited, Prometheon Pharma, LLC, Radius Health, Inc., Regulus Therapeutics Inc., Reviva Pharmaceuticals Inc., Rhythm Pharmaceuticals, Inc., Saniona AB, Sanofi, Shanghai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sinil Pharmaceutical Co., Ltd, Sirona Biochem Corp, Sorrento Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Suven Life Sciences Ltd., Takeda Pharmaceutical Company Limited, Toray Industries, Inc., Umecrine AB, Vicore Pharma AB, Viking Therapeutics, Inc., Virocan Therapeutics Private Limited, WhanIn Pharmaceutical Co., Ltd., Xenetic Biosciences plc, XL-protein GmbH, Zafgen Inc., Zealand Pharma A/S and Zydus Cadila Healthcare Limited.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete research report of 560 pages with TOC is available at http://www.reportsnreports.com/reports/468277-obesity-pipeline-review-h2-2015.html .
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
• The report provides a snapshot of the global therapeutic landscape of Obesity
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Obesity
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Name: Ritesh Tiwari
Email: Send Email
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Release ID: 105953